Guidelines 2.0: Do no net harm - The future of practice guideline development in asthma and other diseases

Current Allergy and Asthma Reports

Volumn 11, Issue 3, 2011, Pages 261-268

  Schünemann, Holger J ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Evidence based medicine; GRADE; Guidelines; Level of evidence

Indexed keywords

ASTHMA; CLINICAL EVALUATION; CONFLICT OF INTEREST; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; REVIEW;

ASTHMA; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 79955898029     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-011-0185-8     Document Type: Review

References (43)

1. Terracciano L, Brozek J, Compalati E, Schunemann H. GRADE system: new paradigm. Curr Opin Allergy Clin Immunol. 2010;10 (4):377-83.
2. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knotterus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2010 Dec 23. This is an introduction to a detailed series on GRADE and guideline development. It includes guidance from question development to group processes.
3. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169(7):677-80. (Pubitemid 37266979)
4. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
5. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso- Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336 (7650):924-6. (Pubitemid 351632017)
6. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-76. These are the new ARIA guidelines developed using the GRADE approach.
7. Schunemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, Stockman L, et al. Transparent development of the WHO rapid advice guidelines. PLoS Med. 2007;4(5):e119.
8. Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, et al. Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders. PLoS Med. 2010;7(8).
9. Fiocchi A, Schunemann HJ, Brozek J, Restani P, Beyer K, Troncone R, et al. Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol. 2010;126(6):1119-28 e12.
10. Fiocchi A, Brozek J, Schunemann H, Bahna SL, von Berg A, Beyer K, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines. Pediatr Allergy Immunol. 2010;21 Suppl 21:1-125.
11. Schunemann HJ, Woodhead M, Anzueto A, Buist S, Macnee W, Rabe KF, et al. A vision statement on guideline development for respiratory disease: the example of COPD. Lancet. 2009;373 (9665):774-9.
12. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis-practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006;355(16):1640-2. (Pubitemid 44583953)
13. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-72.
14. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA. 2006;295(16):1921-8.
15. Sniderman AD, Furberg CD. Why guideline-making requires reform. JAMA. 2009;301(4):429-31.
16. Lo B, Fields M. Conflict of interest in medical research, education and practice. Washington: The National Academies Press, Institute of Medicine; 2009.
17. Lo B, Fields M. Principles for identifying and assessing conflicts of interest. Conflict of interest in medical research, education and practice. Washington: National Academies Press, Institute of Medicine; 2009.
18. Schunemann H, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L, et al. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med. 2009;180(6):564-80.
19. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(7):921-8.
20. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-70. (Pubitemid 36649048)
21. Bradbury J. Storm over WHO-ISH hypertension guidelines. Lancet. 1999;353(9152):563.
22. Horton R. WHO: the casualties and compromises of renewal. The Lancet. 2002;359:1605-11. (Pubitemid 34621131)
23. Laing R, Waning B, Gray A, Ford N, Thoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003;361(9370):1723-9. (Pubitemid 36577449)
24. McCarthy M. Critics slam draft WHO report on homeopathy. The Lancet. 2005;366(9487):705.
25. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281(20):1900-5. (Pubitemid 29242803)
26. Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355(9198):103-6. (Pubitemid 30068554)
27. Baverstock K. A time to ask what you want of WHO. Brit Med J. 2003;327(7406):111.
28. Lantos PM, Charini WA, Medoff G, Moro MH, Mushatt DM, Parsonnet J, et al. Final report of the Lyme disease review panel of the infectious diseases society of America. Clin Infect Dis. 2010;51(1):1-5.
29. Boyd EA, Baumann M, Curtis JR, Field M, Jaeschke R, Osborne M, et al., editors. Guideline Funding and Conflicts of Interest. The American Thoracic Society; 2011 (in press).
30. Boyd EA, Bero LA. Assessing faculty financial relationships with industry: a case study. JAMA. 2000;284(17):2209-14.
31. Campbell EG. Doctors and drug companies-scrutinizing influential relationships. N Engl J Med. 2007;357(18):1796-7. (Pubitemid 350044799)
32. Jacobs AK, Lindsay BD, Bellande BJ, Fonarow GC, Nishimura RA, Shah PM, et al. Task force 3: disclosure of relationships with commercial interests: policy for educational activities and publications. J Am Coll Cardiol. 2004;44(8):1736-40. (Pubitemid 39369813)
33. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7 (1):21-31. (Pubitemid 44932137)
34. Guyatt G, Akl EA, Hirsh J, Kearon C, Crowther M, Gutterman D, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010;152(11):738-41.
35. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336(7651):995-8.
36. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327(7429):1459-61. (Pubitemid 38045824)
37. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349-51. (Pubitemid 46328045)
38. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Bossuyt P, Chang S, et al. GRADE: assessing the quality of evidence for diagnostic recommendations. ACP J Club. 2008;149(6):2.
39. Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst. 2006;4:22.
40. Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4):436-8. (Pubitemid 352040257)
41. Oxman AD, Bjorndal A, Becerra-Posada F, Gibson M, Block MA, Haines A, et al. A framework for mandatory impact evaluation to ensure well informed public policy decisions. Lancet. 2010;375 (9712):427-31.
42. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63 (12):1308-11.
43. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol/ 2010.